about
How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis VaccinesStrategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in the population: The ESCULAPIO project.Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries.Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.Human papilloma virus vaccination: impact and recommendations across the world.Identification of hepatitis B and C screening and patient management guidelines and availability of training for chronic viral hepatitis among health professionals in six European countries: results of a semi-quantitative survey.A retrospective analysis of hospital discharge records for S. pneumoniae diseases in the elderly population of Florence, Italy, 2010-2012The burden of disease of Herpes Zoster in Tuscany.Language support for linguistic minority chronic hepatitis B/C patients: an exploratory study of availability and clinicians' perceptions of language barriers in six European countriesAttitude toward immunization and risk perception of measles, rubella, mumps, varicella, and pertussis in health care workers working in 6 hospitals of Florence, Italy 2011.Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination.Progress in the elimination of measles and congenital rubella in Central ItalyCost-effectiveness of new adult pneumococcal vaccination strategies in Italy.Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.An overview on the implementation of HPV vaccination in Europe.Patient Adherence to Olmesartan/Amlodipine Combinations: Fixed Versus Extemporaneous Combinations.The "Fluad Case" in Italy: Could it have been dealt differently?Hepatitis B: are at-risk individuals vaccinated if screened and found negative for HBV? Results of an online survey conducted in six EU countries.Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy.Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women.Influenza Vaccination and Stillbirth Prevention in High-Income Countries: Is It Really That Effective?Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study.The burden of hospitalization due to HPV infections in Tuscany, Central Italy.Referral of newly diagnosed chronic hepatitis B and C patients in six EU countries: results of the HEPscreen Project.Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care.Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study.Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening.Organizational models of school health services in the WHO European Region.Influenza vaccination 2014-2015: Results of a survey conducted among general practitioners in Italy.Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study.Heat Stress Perception among Native and Migrant Workers in Italian Industries-Case Studies from the Construction and Agricultural Sectors
P50
Q26782340-D1A6C366-42F5-4370-9766-6D30A7F247BCQ30398853-73022B7C-037B-44C0-9DBD-323D28DFC96DQ30485533-F278ED33-4215-4AA7-8101-5D529A0C581CQ33726797-8F99E2E6-5058-4CD0-9E70-836E00C51CE4Q34641738-400355C8-3530-4AB8-BA14-0CEF60B5AC51Q34704575-E3345316-196F-465B-AA04-AC8B8C8C483CQ35749620-FE0F6A1D-CE4D-46C7-8EA5-52CDBD3022D6Q35887505-3729365B-8736-4A4E-8610-050D76BD45F8Q35887530-0059FDF1-DE50-4C38-94D3-DA1CCD5C6249Q36285699-CEBFD61D-902B-45E8-9BA5-5FC51CD1C446Q37159701-73077DD7-43FE-47B9-828F-438392CAE3F2Q37478352-800DFE3D-002E-4E4B-B442-CCA92B0AD04AQ37478363-E3AA6256-52DA-4058-A192-0BBF6517F33AQ37478401-112FB387-8696-4B59-9B4C-1BC3363510D6Q37505409-578ADE90-372A-4DA8-8DAB-566E5ED24586Q37829845-4C62A5F6-91EC-49D5-8DB9-B7938E252209Q38394499-52E7E678-7A70-401B-8E3D-4F043D7BAEDEQ39031164-A03A6E3A-34E0-4EFB-A88C-E1F50EC7A982Q39119212-40F0C23C-24B2-45DC-B1D8-0271A9F50D92Q40001317-5FCDEE2E-CB9B-45CE-9ABD-0497BDC3F887Q40251694-79C68FF9-4718-4EF2-A58C-4A21ECA7A09BQ40335120-C12415CA-27D3-4636-975B-3F4E2E4B5B33Q40336162-86F6FB52-AAFE-42BC-843D-9558C7935BCCQ40417669-38AC6DEF-EFCF-4E86-86AA-F228F902BF03Q40707241-B4999288-634A-43E0-B05E-2C31788072B9Q40765187-F0D563D8-BCDC-4707-9FBE-C991966BA611Q41484950-487CBD45-F917-474D-9E78-50B6BE49DB82Q41651390-CA924BA4-3915-4A0E-B959-AD2DFF37A750Q48611346-FD8B145F-1C9F-40FD-97A1-0C93EE695DD9Q49926294-5F881859-8C4C-4A56-8679-B57E7224959BQ53164378-D778401B-7AF1-4CD1-812A-6452B7200C5EQ64112299-E3594452-F8B4-4716-8E6B-F8777B8CAE87
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Miriam Levi
@ast
Miriam Levi
@en
Miriam Levi
@es
Miriam Levi
@nl
type
label
Miriam Levi
@ast
Miriam Levi
@en
Miriam Levi
@es
Miriam Levi
@nl
prefLabel
Miriam Levi
@ast
Miriam Levi
@en
Miriam Levi
@es
Miriam Levi
@nl
P106
P1153
54893035000
P21
P31
P496
0000-0002-0086-3952